




LEVOCETIRIZINE REDUCES THE COST OF PER AND ITS 
CO-MORBIDITIES FOR SOCIETY AND EMPLOYERS
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Persistent allergic rhinitis (PER) is a frequent disease often asso-
ciated with co-morbidities (asthma, sinusitis, otitis media and
upper respiratory infection) and a signiﬁcant economic burden.
Levocetirizine is an antihistamine, the ﬁrst-line treatment of
allergic rhinitis. OBJECTIVES: To determine the monetary
impact of a long-term levocetirizine treatment either from a soci-
etal perspective or from an employer perspective. METHODS:
XPERT trial was a 6-month double-blind placebo-controlled
trial comparing levocetirizine 5mg once daily to placebo. A total
of 551 patients were included (69% working). Parameters mea-
sured, all related to PER or its co-morbidities, were health care
resources (medications, physician visits and hospitalizations) col-
lected in the case report form as well as workdays and usual daily
activities (UDA) lost collected through a speciﬁc questionnaire.
French monetary values from 2000 were applied and compared
using a bootstrap-t analysis. The societal perspective included all
costs for all patients while the employer perspective included the
cost of workdays lost for working patients. RESULTS: The
overall cost from the societal perspective was of 412.93€ per
patient per month in the placebo vs. 232.23€ in the levocetirizine
group. This led to a gain of 180.70€ per patient per month in
the levocetirizine group (p-value <0.001). UDA lost was the cost
driver (≥ 66%). The overall costs from an employer perspective
was of 152.24€ per working patient per month in the placebo
vs. 89.61€ in the levocetirizine group leading to a gain of 62.63€
per working patient per month (p-value <0.001). CONCLU-
SION: Levocetirizine reduces the overall cost associated with
PER and its co-morbidities both for employers and society. These
savings are due to a reduction in the cost of work and UDA days
lost that more than offset the cost of the levocetirizine treatment.
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PUBLIC HEATH SYSTEM EXPENSES ON CHILDREN’S ATOPIC
DERMATITIS TREATMENT IN VLADIVOSTOK CITY
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OBJECTIVES: Pharmacological and economic analysis of public
health system expenses on children’s atopic dermatitis.
METHODS: Evaluation of cost and expenses on the disease
included expenditures on hospital and ambulatory assistance and
sanatorium-and-spa treatment. In 2000–2003, children’s medical
institutions of Vladivostok city held a survey of 200 families with
children suffering from atopic dermatitis and analysis of medical
documentation. RESULTS: Volume of expenses was determined
to a great extent by severity of the disease clinical course and
spread of atopic dermatitis. Number of recourses to medical
assistance with light course of the disease was in most cases not
more that four times per year and was restricted to outpatient
treatment only, the cost of treatment amounted to 600–1400
rubles ($20–47) per child per year. In case of severe course and
poor control over the disease number of recourses increased up
to 14–20 per year, the expenses included cost of consultations of
allergologist and dermatologist and amounted up to 2100–7000
rubles ($322–406) per year. Further worsening of case required
hospital treatment expenses. On average, 0.37 cases of hospital
treatment fall at one child with atopic dermatitis per year, with
severe clinical course this value increased up to 1.34 ± 0.2 cases,
treatment duration was 15.62 ± 1.02 days. Average cost of hos-
pital treatment per a child suffering from atopic dermatitis 
in 2000–2003 was 2775.84–3675.69 rubles ($86–124),
1922.7–2896.1 rubles ($60–98) and 3793.1–5713.5 rubles
($118–193) in allergologic, dermatologic and pediatric divisions
respectively. Expenses on 21 days of sanatorium-and-spa treat-
ment in Primorsky region amounted to 12,000 rubles ($406) and
were registered in 2.4% of families with children suffering from
atopic dermatitis. CONCLUSIONS: Atopic dermatitis requires
considerable expenses on medical treatment from public health




RESOURCE USE IN PATIENTS WITH EXACERBATIONS OF
ASTHMA WITH DIFFERENT UNDERLYING DEGREES OF
SEVERITY IN FIVE EUROPEAN COUNTRIES
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OBJECTIVE: Patients with asthma consume signiﬁcant amounts
of health care resources. The purpose of this study was to inves-
tigate differences in resource use for patients with different
degrees of severity of asthma. METHODS: The data are drawn
from the Adelphi Disease Speciﬁc Programme (DSP) in Asthma,
undertaken in 2003. DSPs are cross-sectional studies of consult-
ing patients. One of the aims of the DSP was to collect infor-
mation about the treatment of asthma from the perspective of
both the doctor and the patient. Data were collected by a panel
of doctors who were asked to include the ﬁrst 10 patients con-
sulting for asthma from a speciﬁed start date. The study included
2610 patients with asthma of greater than 12 months duration
in France, UK, Germany, Italy and Spain. RESULTS: Patients
were segmented by their doctor into one of four categories: inter-
mittent (28%), mild persistent (15%), moderate persistent
(49%) and severe persistent (8%). Patients with intermittent
asthma had a mean of 0.37 emergency room visits, 0.06 hospi-
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